![]() In comparison, the United States focuses more on advanced-therapy medicinal products (about 20 percent of all biotech companies and all funding) than Europe does. ![]() These together represent half of the biotech companies in Europe (Exhibit 1). The three largest focus on providing services, on immunotherapies, and on brain and neuronal therapies. Through this exercise, we found that European biotechs can be grouped into eight clusters. (Also see our special report on the biotech market in Benelux, Scaling innovation: How Benelux could become Europe’s leading biotech hub.) This cluster map also shined light on the industry’s possible future directions. To see through the complexity, we grouped approximately 1,000 European biotech companies into clusters by country, modality, and therapeutic area so as to map biotech hot spots and trace how trends in the region are shifting over time. Hot spots in a fragmented landscapeĮurope has a complex biotech landscape: hundreds of companies, multiple paths to innovation and financing, and marked differences among countries. Our research indicated that three factors make Europe’s biotech market attractive to investors: strong hot spots across geographies, modalities, and therapeutic areas powerhouse research and industry expertise to support basic science and innovation and an abundance of high-caliber talent. This article shares highlights and reflections from our recent report on Europe’s biotech industry, Biotech in Europe: Scaling innovation, which focused on these three questions: What makes European biotech attractive, what financing does it need to fuel growth, and what should biotech leaders and investors do to succeed? What makes European biotech attractive? However, European companies have an opportunity to play an even stronger role in the growth of an important and dynamic industry. Europe’s role in this industry continues to grow, and the region leads in many ways. Yet more scientific and technological breakthroughs are on the horizon. CAR-T 2 Chimeric antigen receptor T cells.-into powerful new therapeutic tools. SMEs (, Empirica, Gnubila, Infocert, Medicus, Motek Entertainment, Peachnote, PromoFarma, Sensolus, XLAB).Biotech is entering its next S-curve of growth as companies work to transform an array of innovations-gene therapies, stem-cell treatments, antisense DNA, siRNA, 1 Small interfering ribonucleic acid. Scientific societies (American College of Cardiology, European Society of Cardiology, VPHI) Research centres (Athena Research Center, Atos, Austrian Institute of Technology, Barcelona Supercomputing Center, CENSIS, Centro Europa Ricerche, Centre for Social Studies and Policies, Centro Nazionale delle Ricerche, Fraunhofer Mevis, Gulf Research Center, Hanover Clinical Trial Center, Institut de la Mediterranée, INRIA, KPMG Italia, SBA Research) Procurement agencies (CONSIP and Regione Emilia Romagna-Intercent-ER) Performance companies (Balletto di Roma, Instituto Stocos, K-Danse, Lykeion ton Hellenidon) ![]() International organisations (CERN, UNICEF, World Bank), Industries (Be-Almerys, ESI Group, Philips Electronics Netherlands B.V., Siemens AG, Siemens Healthineers) Hospitals (Charité Universitätsmedizin Berlin, Deutsche Herzzentrum Berlin, Great Ormond Street Hospital, Hôpital Necker Enfants Malades, IRCCS Istituto Giannina Gaslini, IRCCS Ospedale San Raffaele, Ospedale Pediatrico Bambino Gesù, Universitätsklinikum Hamburg-Eppendorf) In the course of its multiple activities, Lynkeus has been interacting with over 100 partners and customers, ranging from:Īcademia (Coventry University, Delft University of Technology, Erasmus Universitair Medisch Centrum Rotterdam, HES-SO, Johns Hopkins University, Katholieke Universiteit Leuven, London School of Economics, McGill University, Politecnico di Milano, Queen Mary University of London, Technische Universität München, Transylvania University of Brasov, University of Athens, Universitat de Barcelona, University of Graz, University of Luxembourg, Università di Roma La Sapienza, Universitat Pompeu Fabra, University of Sheffield, Università degli Studi di Genova, UMC Utrecht, University of West England, Vrije Universiteit Amsterdam)įinancial entities (Citibank and VISA Europe)įoundations (ASTRID, European Genetic Foundation, Fondazione Bruno Kessler, Fondazione Gerolamo Gaslini, Fondazione Policlinico Gemelli, Stiftung Secure Information and Communication Technologies)
0 Comments
Leave a Reply. |